Ondansetron Hydrochloride/Pyridostigmine Bromide

盐酸昂丹司琼/溴吡斯的明

Report date: 2025/09/12 20:01:19

Base Information

Drug NameOndansetron Hydrochloride/Pyridostigmine Bromide
Drug Alias NameOndansetron/Pyridostigmine吡斯的明+昂丹司琼Pyridostigmine+Ondansetron吡斯的明-昂丹司琼Pyridostigmine-Ondansetron +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 3 (5-HT3) receptor antagonistsAcetylcholinesterase inhibitors
TargetsAcetylcholinesteraseSerotonin 3 (5-HT3) receptor
Therapy Area/IndicationsMyasthenia Gravis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Ondansetron HydrochloridePyridostigmine Bromide
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGt Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDas-Mg IncDas Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsMyasthenia Gravis

Other Information

ATC CodeN/A
Related LinksN/A